NO20042166L - Kombinasjonsterapi for behandling av sykdom - Google Patents

Kombinasjonsterapi for behandling av sykdom

Info

Publication number
NO20042166L
NO20042166L NO20042166A NO20042166A NO20042166L NO 20042166 L NO20042166 L NO 20042166L NO 20042166 A NO20042166 A NO 20042166A NO 20042166 A NO20042166 A NO 20042166A NO 20042166 L NO20042166 L NO 20042166L
Authority
NO
Norway
Prior art keywords
disease
treatment
combination therapy
therapy
combination
Prior art date
Application number
NO20042166A
Other languages
English (en)
Norwegian (no)
Inventor
Antoine A Noujaim
Christopher F Nicodemus
Birgit C Schultes
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of NO20042166L publication Critical patent/NO20042166L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042166A 2001-10-26 2004-05-25 Kombinasjonsterapi for behandling av sykdom NO20042166L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33924001P 2001-10-26 2001-10-26
PCT/IB2002/005794 WO2003034977A2 (en) 2001-10-26 2002-10-28 Combination therapy for treating disease

Publications (1)

Publication Number Publication Date
NO20042166L true NO20042166L (no) 2004-05-25

Family

ID=23328122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042166A NO20042166L (no) 2001-10-26 2004-05-25 Kombinasjonsterapi for behandling av sykdom

Country Status (9)

Country Link
AT (1) AT500649A1 (es)
AU (1) AU2002358246B2 (es)
CA (1) CA2464947C (es)
CH (1) CH696871A5 (es)
DE (1) DE10297379T5 (es)
ES (1) ES2304264A1 (es)
GB (1) GB2397018B (es)
NO (1) NO20042166L (es)
WO (1) WO2003034977A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2008091643A2 (en) * 2007-01-23 2008-07-31 Altarex Medical Corp. In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027637A1 (en) * 1993-05-27 1994-12-08 Uwe Wagner Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
US20020022235A1 (en) * 2000-02-08 2002-02-21 Antoine Noujaim Method for diagnosing efficacy of xenotypic antibody therapy
CN100340575C (zh) * 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
AU5286999A (en) * 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
ATE290879T1 (de) * 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
CA2441393A1 (en) * 2001-03-21 2002-10-03 Altarex Corp. Therapeutic compositions that alter the immune response

Also Published As

Publication number Publication date
CH696871A5 (de) 2008-01-15
ES2304264A1 (es) 2008-10-01
AT500649A1 (de) 2006-02-15
AU2002358246B2 (en) 2008-02-28
WO2003034977A3 (en) 2004-05-27
CA2464947A1 (en) 2003-05-01
DE10297379T5 (de) 2004-10-14
CA2464947C (en) 2012-05-22
GB0409191D0 (en) 2004-05-26
GB2397018A (en) 2004-07-14
GB2397018B (en) 2006-05-31
WO2003034977A2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
CY2019030I2 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
NO20033594D0 (no) Fenetanolamin-derivater for behandling av luftveissykdommer
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20034590L (no) Fremgangsmåter for behandling av vaskul¶r sykdom
NO20034780D0 (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
NO20033804L (no) Karbamatforbindelser for behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20020784D0 (no) Medikament for behandling av brudd
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
NO20043113L (no) Fremgangsmate for behandling av benforstyrrelse
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application